The clinical catalysts (REGAIN data, ReSTART enrollment completion, PMDA approval) are positive but pre-revenue biotech with widening losses and non-cash warrant volatility. Key binary events: ReSTART top-line data around end-2026 and IMPACT pancreatic enrollment completion in Q3 2026. Monitor cash burn trajectory and any secondary offering risk given $80.2M cash position.
Price Chart
Executive Summary
Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from $8.7M ($0.12/share) YoY, driven by a $9.6M non-cash remeasurement of warrants liability and increased R&D spend. Operationally, the company highlighted strong interim REGAIN glioblastoma data (67% complete response rate), completion of enrollment in the pivotal ReSTART cSCC trial (88 patients), and PMDA approval in Japan. Cash of $80.2M provides runway into 2027.
Key Facts
- Net loss of $22.9M in Q1 2026 vs $8.7M in Q1 2025; EPS -$0.26 vs -$0.12
- Operating loss widened to $13.3M from $9.3M YoY, driven by R&D spend up to $11.0M from $7.2M
- Financial expense of $9.6M vs income of $0.7M YoY due to warrants liability remeasurement
- Cash, equivalents, short-term and restricted deposits of $80.2M at March 31, 2026 vs $76.9M at Dec 31, 2025
- REGAIN glioblastoma trial: 100% local disease control, 67% complete response rate in first 3 patients
- ReSTART pivotal cSCC trial completed enrollment with 88 patients; first module of PMA submitted Jan 2026
- PMDA marketing approval received in Japan for head and neck cancer; post-market surveillance study ongoing
- Shares outstanding increased to 90.2M from 88.0M at Dec 31, 2025
- Warrants liability increased to $15.7M from $5.4M at Dec 31, 2025
Financial Impact
Net loss increased by $14.2M YoY; operating cash burn ~$13.3M/quarter; cash runway ~6 quarters at current burn rate
Risk Factors
- Pre-revenue company with no approved products in the US; commercialization dependent on FDA PMA approval
- Widening net loss and operating loss; cash burn rate may require additional financing within 12-18 months
- Warrants liability creates significant non-cash earnings volatility ($15.7M at Q1 end)
- Clinical trial risks: REGAIN and IMPACT data are early-stage; ReSTART pivotal data may not meet endpoints
- Share count increased 2.5% since year-end, potential dilution from warrant exercises or future offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-058424 |
| Document: ea0290584-6k_alpha.htm | 0001213900-26-058424 |
| Document: 0001213900-26-058424-index-headers.html | 0001213900-26-058424 |
| Document: 0001213900-26-058424-index.html | 0001213900-26-058424 |
| Document: 0001213900-26-058424.txt | 0001213900-26-058424 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access